RXi and miRagen Announce Formation of Research Collaboration in the Field of microRNAs
News Apr 13, 2010
RXi Pharmaceuticals Corporation and miRagen Therapeutics, Inc. have announced that they have entered into a research collaboration.
Under this agreement, the parties will evaluate the potential utility of RXi’s proprietary rxRNA™ technology against specific miRNA targets of interest to miRagen in the cardiac and neuromuscular disease areas. Each party will contribute its technology and resources to the collaboration to generate novel miRNA compounds. Financial terms of the collaboration were not disclosed.
“We look forward to working with miRagen in exploring the potential of validating our proprietary rxRNA compounds in the field of miRNA, as success with this approach may allow us to expand the utility of RXi’s therapeutic platform, as well as the commercial scope of product opportunities.”
“miRNAs, which are natural RNAi triggers, have been recently implicated in a variety of human diseases, including cancer, inflammation, as well as metabolic and cardiovascular disorders,” said Noah Beerman, President and Chief Executive Officer of RXi. “We look forward to working with miRagen in exploring the potential of validating our proprietary rxRNA compounds in the field of miRNA, as success with this approach may allow us to expand the utility of RXi’s therapeutic platform, as well as the commercial scope of product opportunities.”
“miRagen is committed to evaluating and deploying the most advanced technologies available to support our mission of developing microRNA-based therapeutics,” said William S. Marshall, Ph.D., President and CEO of miRagen Therapeutics. “We are enthusiastic about the potential for the rxRNA technology to produce miRNA mimicry and thus are keenly interested in working with RXi to further investigate its properties.”
Big Data Study Targets Genomic Dark Matter from Ocean Floor to Gut FloraNews
An international team led by computational biologist Fran Supek at IRB Barcelona develop a machine learning method to predict unknown gene functions of microbes.The system examines and compares ‘big data’ available on the metagenomes of human and environmental microbiomes.READ MORE
New Retinal Ganglion Cell Subtypes Emerge From Single-Cell RNA SequencingNews
40 subtypes of retinal ganglion cells classified, raising questions about what constitutes a cell type or subtypeREAD MORE
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.